Mark Fineman: Ledger

Stories naming Mark Fineman. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Senior Vice President, Clinical Affairs (former)	Biosplice Therapeutics	Brandon BioCatalyst portfolio
Executive Director of Medical Development and R&D Strategic Relations (former)	Amylin	Brandon BioCatalyst portfolio
Chief Scientific Officer (former)	Elcelyx Therapeutics	Brandon BioCatalyst portfolio
Chief Development Officer	Glyscend	Brandon BioCatalyst portfolio

Key hire

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.

Brandon BioCatalyst portfolio Thu 12 May 2022 Amylin Biosplice Therapeutics Elcelyx Therapeutics Glyscend Johns Hopkins University THRUST Strategic Communications Ashish Nimgaonkar Mark Fineman Monique Allaire

Mark Fineman

Roles

Coverage

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment